Sub-Navigation

• Investor News
• Ad-hoc Publications
• Archive

Bayer Links

• Bayer Global
• Nachhaltigkeit
• Presse
• Bayer@Social Media

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Investor News

Search

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Friday May 24, 2013

Not intended for U.S. and UK Media

Bayer's Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome

Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant

Monday May 20, 2013

Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:

Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat

Riociguat showed good long-term safety profile (1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH) (1)

Friday May 17, 2013

Not intended for U.S. and UK Media

Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan

Thursday May 16, 2013

Strategic move to strengthen Consumer Care business:

Bayer to acquire Steigerwald Arzneimittelwerk GmbH

Transaction includes Iberogast® and Laif® brands

Thursday May 16, 2013

Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):

Bayer to Present New Data Across Oncology Portfolio at ASCO 2013

First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types

Wednesday May 15, 2013

Not intended for U.S. and UK Media

Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection

New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival

Wednesday May 15, 2013

Not intended for U.S. and UK Media

Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer

Wednesday May 08, 2013

Not intended for U.S. and UK Media - The American Thoracic Society International Conference 2013:

Bayer to Present Data on Pulmonary Hypertension Research at the ATS International Conference 2013 in Philadelphia

Interim Analysis from Long-Term Extension Study PATENT-2 Phase III / Hemodynamic data and clinical correlation from CHEST-1 Phase III / New Data Sets from Pivotal PATENT-1 Phase III

Tuesday May 07, 2013

Not intended for UK Media

Bayer commences cash tender offer for all outstanding shares of Conceptus, Inc.

Friday May 03, 2013

Not intended for UK Media

Bayer Provides Update on Phase II/III Trial of BAY 86-6150

Monday April 29, 2013

Not intended for UK media - Strategic expansion of Women's Health business:

Bayer to acquire Conceptus, Inc.

Adds Essure®, the only non-surgical permanent birth control method, to Bayer's contraception portfolio

Friday April 26, 2013

Dr. Marijn Dekkers at the Annual Stockholders' Meeting of Bayer AG:

"Bayer is a world-class innovation company"

2012 operationally a very successful year / Highest sales in the company's 150-year history / Proposal to raise dividend for 2012 to EUR 1.90 per share / Employees to benefit from the company's success with bonuses totaling over EUR 700 million / Life Sciences off to a good start in anniversary year

Thursday April 25, 2013

First quarter of 2013:

Bayer: Life Sciences off to a good start in anniversary year

New pharmaceutical products spur growth at HealthCare, continuing strong development at CropScience, cost pressure at MaterialScience / Group sales up 2.1 percent to EUR 10,266 million / EBIT improves by 8.6 percent to EUR 1,771 million / EBITDA before special items increased by 0.4 percent to EUR 2,453 million / Net income rises 11.5 percent to EUR 1,160 million / Gratifying development in Emerging Markets / Group outlook for 2013 confirmed

Tuesday April 16, 2013

Bayer CropScience and Monsanto Enter into Cross-Licensing Agreements for Next-Generation and Enabling Technologies

Agreements Create More Options for Farmers / Expanded Market Opportunities for Next-Generation Technologies

Tuesday April 16, 2013

Not intended for U.S. and UK Media

First Patient Enrolled in Global Phase III Program Evaluating Bayer's Amikacin Inhale in Intubated and Mechanically Ventilated Patients with Gram-negative Pneumonia

Treatments to complement current standard of care urgently needed as morbidity and mortality is significant in this patient population

Monday April 08, 2013

Not intended for U.S. and UK Media

U. S. FDA Grants Priority Review to Bayer's Riociguat for the Treatment of two Life-Threatening Pulmonary Hypertension Indications

Thursday March 28, 2013

Bayer CropScience and Syngenta propose a comprehensive action plan to help unlock EU stalemate on bee health

Monday March 25, 2013

Not intended for U.S. and UK Media

Bayer's Stivarga® (regorafenib) Tablets Approved in Japan for the Treatment of Advanced or Recurrent Colorectal Cancer

Friday March 22, 2013

Not intended for U.S. and UK Media - Acute Coronary Syndrome (ACS)

Bayer's Xarelto® (Rivaroxaban) Recommended for Approval in the EU for the Prevention of Atherothrombotic Events after an ACS

Xarelto 2.5 mg twice-daily (BID) demonstrated significant clinical benefit for patients with ACS when used with standard antiplatelet therapy / Complementary modes of action of Xarelto 2.5 mg BID and antiplatelet therapy have the potential to provide more complete protection against long-term clot formation / Final decision from the European Commission expected in the first half of 2013

Friday March 08, 2013

Not intended for U.S. and UK Media

Bayer Initiates Xarelto® (Rivaroxaban) Study in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stent Placement

Friday March 08, 2013

Not intended for U.S. and UK Media

New Pivotal Phase III Study Initiated with Bayer's Xarelto® (Rivaroxaban) in Patients with Chronic Heart Failure and Significant Coronary Artery Disease

Low-dose rivaroxaban given fast track designation by U.S. FDA as first novel oral anticoagulant to be evaluated in this high-risk patient group

Tuesday March 05, 2013

Not intended for U.S. and UK Media: Acute Coronary Syndrome (ACS):

U.S. FDA Issues Complete Response Letter for Bayer's Xarelto® (Rivaroxaban) for the Reduction of Cardiovascular Events in Patients with ACS

Monday March 04, 2013

Not intended for U.S. and UK Media - Long-term extension study of Riociguat in patients with CTEPH:

Interim results from CHEST-2 study support benefits of Bayer's Riociguat as demonstrated in Phase III CHEST-1 study

Riociguat showed significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with inoperable or residual chronic thromboembolic pulmonary hypertension (CTEPH) (1) / Riociguat showed good long-term safety profile (1)

Thursday February 28, 2013

New products create optimism for the future

Bayer: continuing growth momentum

Group targets achieved in 2012 - sales and earnings before special items increase in all subgroups / Sales increase by 8.8 percent to EUR 39,760 million / EBIT EUR 3,960 million (minus 4.6 percent) - Net income EUR 2,446 million (minus 1.0 percent) / Further accounting measures for legal claims / EBITDA before special items rises by 8.8 percent to EUR 8,284 million / Core earnings per share improve by 10.8 percent to EUR 5.35 / Encouraging growth in the emerging markets / Steady progress with innovation pipeline strengthens life-science businesses / Forecast for anniversary year 2013: continuing record development

Tuesday February 26, 2013

Bayer proposes dividend increase to EUR 1.90 per share for 2012

Payout up 15 percent to EUR 1,571 million

Tuesday February 26, 2013

Not Intended for U.S. and U.K. Media

Bayer's Regorafenib Granted Priority Review in Japan for the Treatment of Patients with Gastrointestinal Stromal Tumors

Monday February 25, 2013

Not intended for U.S. and UK media

Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Gastrointestinal Stromal Tumors

Stivarga shown in a pivotal Phase III trial to significantly improve progression-free survival in patients with gastrointestinal stromal tumors (GIST) whose disease had progressed after previous treatments

Tuesday February 19, 2013

Not intended for U.S. and UK Media

Bayer and Regeneron Initiate Phase III Trial of VEGF Trap-Eye (Aflibercept) for the Treatment of Diabetic Macular Edema in Asia and Russia

Wednesday February 13, 2013

Not intended for U.S. and UK Media - Castration-Resistant Prostate Cancer with Bone Metastases:

Radium-223 Dichloride Granted Priority Review by U.S. FDA

Monday February 11, 2013

Not intended for U.S. and UK media

Bayer's Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension Submitted For Regulatory Approval in the U.S. and EU

Riociguat is the first drug that has consistently demonstrated efficacy in two life-threatening PH indications - chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)

Tuesday February 05, 2013

Not intended for U.S. and UK Media

Xarelto® to be Studied with Factor Xa Inhibitor Antidote

Bayer and Janssen announce clinical collaboration agreement with Portola

Friday February 01, 2013

Not intended for U.S. and UK media - IMCAS Congress 2013

Positive results of Phase-III trials suggest that ATX-101 is effective as a non-surgical treatment for the reduction of unwanted submental fat

Wednesday January 23, 2013

Dr. Jörg Reinhardt to leave Bayer HealthCare

Thursday January 10, 2013

Not intended for U.S. and UK media

Bayer receives approval for new long-term contraceptive Skyla^TM in the U.S.

New low dose levonorgestrel-releasing intrauterine system (IUS) / Longterm contraception for up to three years

Monday January 07, 2013

Not intended for U.S. and UK media

Bayer Submits VEGF Trap-Eye (aflibercept) for Treatment of Macular Edema Following Central Retinal Vein Occlusion in Japan

Friday January 04, 2013

Not intended for U.S. media

Bayer HealthCare completes acquisition of Teva's U.S. animal health business

New product lines strengthen Bayer's animal health business in the U.S.

Thursday January 03, 2013

Not intended for U.S. and UK media

Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer